RT Journal Article
SR Electronic
T1 Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.08.24316916
DO 10.1101/2024.11.08.24316916
A1 Constantine-Cooke, Nathan
A1 Plevris, Nikolas
A1 Monterrubio-Gómez, Karla
A1 Belinchón, Clara Ramos
A1 Ong, Solomon
A1 Elford, Alexander T.
A1 Gros, Beatriz
A1 Jones, Gareth-Rhys
A1 Lees, Charlie W.
A1 Vallejos, Catalina A.
YR 2024
UL http://medrxiv.org/content/early/2024/11/11/2024.11.08.24316916.abstract
AB Background Crohn’s disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic and unpredictable, with a marked disconnect between symptoms and intestinal inflammation. Attempts to classify inflammatory bowel disease (IBD) subphenotypes to inform clinical decision making have been limited. We aimed to describe the latent disease heterogeneity by modelling routinely collected faecal calprotectin (FC) and CRP data, describing dynamic longitudinal inflammatory patterns in IBD.Methods In this retrospective study, we analysed patient-level longitudinal measurements of FC and CRP recorded within seven years since diagnosis. Latent class mixed models (LCMMs) were used to cluster individuals with similar longitudinal FC or CRP profiles. Associations between cluster assignment and information available at diagnosis (e.g. age, sex, and Montreal classification) were quantified using multinomial logistic regression. Differences in advanced therapy use across clusters were also explored using cumulative distributions over time. Finally, we considered uncertainty in cluster assignments with respect to follow-up length and explored the overlap between clusters identified based on FC and CRP.Findings We included 1036 patients (544 CD, 380 UC, 112 IBD-unclassified (IBDU)) in the FC analysis with a total of 10545 FC observations (median 9 per subject, IQR 6–13). The CRP analysis consisted of 1838 patients (805 CD, 847 UC, 186 IBDU) with 49364 CRP measurements (median 20 per subject; IQR 10–36). Eight distinct clusters of inflammatory behaviour over time were identified by LCMM in each analysis. The clusters, FC1-8 and CRP1-8, were ordered from the lowest cumulative inflammatory burden to the highest. The clusters included groups with high diagnostic levels of inflammation which rapidly normalised, groups where high inflammation levels persisted throughout the full seven years of observation, and a series of intermediates including delayed remitters and relapsing remitters.CD and UC patients were unevenly distributed across the clusters. In CD, whilst patients with upper GI involvement (L4) were less likely to be in FC1 and FC2, there was no impact on ileal versus colonic disease on cluster assignment. In UC, male sex was associated with the poorest prognostic cluster (FC8). The use and timing of advanced therapy was associated with cluster assignment, with the highest use of early advanced therapy in FC1. Of note, FC8 and CRP8 captured consistently high patterns of inflammation despite a high proportion of patients receiving advanced therapy, particularly for CD individuals (56.8% and 33.3%, respectively). We observed that uncertainty in cluster assignments was higher for individuals with short longitudinal follow-up, particularly between clusters capturing similar earlier inflammation patterns. There was broadly poor agreement between FC and CRP clusters in keeping with the need to monitor both in clinical practice.Interpretation Distinct patterns of inflammatory behaviour over time are evident in patients with IBD. Cluster assignment is associated with disease type and both the use and timing of advanced therapy. These data pave the way for a deeper understanding of disease heterogeneity in IBD and enhanced patient stratification in the clinic.Competing Interest StatementNP has served as a speaker for Janssen, Takeda and Pfizer. BG has acted as consultant to Galapagos and Abbvie and as speaker for Abbvie, Jansen, Takeda, Pfizer and Galapagos. G-RJ has served as a speaker for Takeda, Janssen, Abbvie, Fresnius and Ferring. CWL has acted as a speaker and/or consultant to AbbVie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Sandoz, Celltrion, Cellgene, Amgen, Samsung Bioepis, Fresenius Kabi, Tillotts, Kuma Health, Trellus Health and Iterative Health. None of the other authors report any conflicts of interest.Funding StatementCWL is funded by a UKRI (UK Research and Innovation) Future Leaders Fellowship 'Predicting outcomes in IBD' (MR/S034919/1). G-RJ is funded by a Wellcome Trust Clinical Research Career Development Fellowship. NC-C was partially supported by the Medical Research Council and The University of Edinburgh via a Precision Medicine PhD studentship (MR/N013166/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the local Caldicott Guardian (Project ID: CRD18002, registered NHS Lothian information asset #IAR-954)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes